2BO Stock Chart & Stats
€2.04
-€0.06(-3.23%)
At close: 4:00 PM EDT
€2.04
-€0.06(-3.23%)
Day’s Range― - ―
52-Week Range€1.07 - €4.44
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
€40.03M
Enterprise Value€11.97M
Total Cash (Recent Filing)€23.02M
Total Debt (Recent Filing)€3.21M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 18, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume0
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.46Price Target Upside314.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage preserves financial flexibility because the company is not heavily burdened by interest obligations or debt repayment. This gives management more room to direct capital toward research and development, although operating losses still require careful funding decisions.
POZ Drug-delivery PlatformThe POZ platform provides a reusable technology foundation for developing long-acting and targeted therapeutics across existing or novel drugs. If successfully translated into candidates and partnerships, this platform model could support multiple opportunities rather than relying on one product.
Simplified Capital StructureEliminating the Series A preferred designation simplifies the equity structure and clarifies the rights of common shareholders. The restored preferred-share pool also gives Serina greater flexibility for future corporate or financing actions, supporting cleaner governance over time.
Bears Say
No Current Revenue And Large LossesThe absence of current revenue and the size of operating losses show that Serina remains pre-commercial and has not yet established a self-funding business. Continued dependence on development financing increases execution pressure and leaves results vulnerable to delays in product advancement.
Persistent Cash BurnLarge negative operating and free cash flow indicate that reported losses are translating into substantial cash outflows. This reduces financial durability, limits internally funded investment, and makes continued access to external capital important for sustaining research and corporate operations.
Equity Financing And Dilution RiskThe equity purchase agreement provides financing flexibility but can expand the common-share count as capital is raised. That mechanism may fund operations without debt, yet recurring share issuance can dilute existing holders and signals that internal cash generation is currently insufficient.
Serina Therapeutics News
2BO FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was €1.07 and its highest was €4.44 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is €40.03M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.473 earnings per share for the quarter, missing the consensus estimate of -€0.4 by -€0.072.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 25,400,473 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -€0.473 in its last earnings report, missing expectations of -€0.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in DE:2BO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.87%
12-Months-Change
Fundamentals
Return on Equity
-222.42%
Trailing 12-Months
Asset Growth
188.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
2BO Stock 12 Month Forecast
Average Price Target
€8.46
▲(314.82% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
―
Jupiter Neurosciences, Inc.
―